瑞舒伐他汀对代谢综合征患者颈动脉内膜中层厚度及血管内皮功能的影响

Influence of rosuvastatin on carotid intima-media thickness and vascular endothelial function in patients with metabolic syndrome

目的 探讨瑞舒伐他汀对代谢综合征（MS）患者颈动脉内膜中层厚度（CIMT）及血管内皮功能的影响.方法 选择2015年11月至2016年12月海阳市人民医院收治的MS患者86例,将其分为瑞舒伐他汀组（10 mg/d）和生活方式干预组,随访6个月,超声检测CIMT及肱动脉内径,血液学检测内皮素-1（ET-1）、一氧化氮（NO）、同型半胱氨酸（Hcy）、超敏C-反应蛋白（hs-CRP）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-18（IL-18）水平,比较两组试验前后各指标的差异.结果 治疗后6个月,瑞舒伐他汀组与治疗前比较,最大CI-MT及ET-1、Hcy、hs-CRP、TNF-α、IL-6、IL-18水平均降低（P均〈0.05）,而NO水平升高（P〈0.05）,充血后肱动脉内径增大（P〈0.05）;与生活方式干预组比较,瑞舒伐他汀组上述指标均有显著改善（P均〈0.05）.瑞舒伐他汀组无严重不良反应.结论 瑞舒伐他汀可逆转CIMT,改善血管内皮功能,抑制炎症反应,安全性良好.

Objective To study the influence of rosuvastatin on carotid intima-media thickness （ CIMT） and vascular endothelial function in patients with metabolic syndrome （ MS） .Methods Eighty-six patients with MS admitted to Haiyang People ＇s Hospital from November 2015 to December 2016 were selected and were divided into rosuvastatin group （ receiving rosuvastatin 10 mg/d ） and life style-intervented group , pateints were followed up for 6 months continuosly .Ultrasound indicators , including CIMT and brachial artery diameter , and blood indicators including endothelin-1 （ ET-1 ） , nitric oxide （ NO） , homocysteine （ Hcy ） , high-sensitivity C-reactive protein （ hs-CRP ） , tumor necrosis factor-α（ TNF-α） , interleukin-6 （ IL-6） , interleukin-18 （ IL-18） were measured and compared before and after treatment.Results After 6-month treatment, the maximal CIMT and levels of ET-1, Hcy, hs-CRP, TNF-α, IL-6 and IL-18 were significantly decreased （ P all 〈0.05） , while NO level and brachial artery diameter were significantly increased in rosuvastatin group （ P〈0.05 ） . Compared with life style-intervente d group , there were significant improvements of the above indicators in rosuvastatin group （ P〈0.05 ） .There was no serious adverse event in rosuvastatin group .Conclusions Rosuvastatin can reverse CIMT, improve vascular endothelial function and inhibit imflammatory response , and it is safe .